网站综合信息 www.orexigen.com
- 标题:
- Orexigen Therapeutics, Inc. - Home
- 关键字:
- Orexigen Therapeutics Inc
- 描述:
- Orexigen Therapeutics, Inc.
- 域名信息
- 域名年龄:22年1个月8天 注册日期:2002年09月01日 到期时间:2012年09月01日
邮箱:dpirie 电话:+1.8588758600
注册商:REGISTER.COM, INC.
- 服务器空间
- IP:199.79.50.67
地址:美国
- 备案信息
- 备案号:-
域名流量Alexa排名
域名注册Whois信息
orexigen.com
域名年龄: 22年1个月8天注册时间: 2002-09-01
到期时间: 2012-09-01
注 册 商: REGISTER.COM, INC.
注册邮箱: dpirie
联系电话: +1.8588758600
获取时间: 2011年09月27日 05:08:29
Domain Name: OREXIGEN.COM
Registrar: REGISTER.COM, INC.
Whois Server: whois.register.com
Referral URL: http://www.register.com
Name Server: DNS129.B.REGISTER.COM
Name Server: DNS226.C.REGISTER.COM
Name Server: DNS239.A.REGISTER.COM
Name Server: DNS249.D.REGISTER.COM
Status: clientTransferProhibited
Updated Date: 2011-09-02
Creation Date: 2002-09-01
Expiration Date: 2012-09-01
>>> Last update of whois database: Mon, 2011-Sep-26 21:07:45 UTC <<<
Registrant:
Orexigen Therapeutics Inc.
Dave Pirie
3344 N. Torrey Pines Court Suite 200
La Jolla, CA 92037
US
Phone: +1.8588758600
Email: dpirie
Registrar Name....: Register.com
Registrar Whois...: whois.register.com
Registrar Homepage: www.register.com
Domain Name: orexigen.com
Created on..............: 2002-09-01
Expires on..............: 2012-09-01
Administrative Contact:
Orexigen Therapeutics Inc.
Dave Pirie
12481 High Bluff Drive Suite 150
San Diego, CA 92130
US
Phone: 1-619-2475100
Email: dpirie
Technical Contact:
Register.Com
Domain Registrar
575 8th Avenue 11th Floor
New York, NY 10018
US
Phone: 1-902-7492701
Email: domain-registrar
DNS Servers:
dns226.c.register.com
dns129.b.register.com
dns249.d.register.com
dns239.a.register.com
Visit AboutUs.org for more information about orexigen.com
AboutUs: orexigen.com
Register your domain name at http://www.register.com
网站头文件(HTTP Header)
HTTP/1.1 200 OK 访问时间:2014年04月16日 18:05:01 设置Cookie:1aed9e9820a7f5f80bffe6575b9dc3f3=o90ti824gd6cstt44mcru36320; path=/ 隐私:CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM" Content-Encoding: gzip X-Content-Encoded-By: Joomla! 2.5 缓存控制:不缓存 其他指令:不缓存 文件大小:5718 Keep-Alive: timeout=15, max=100 连接:Keep-Alive 类型:text/html; charset=utf-8 网站编码:utf-8
同IP网站(同服务器)
其他后缀域名
网站首页快照(纯文字版)
抓取时间:2014年04月16日 18:00:23
网址:http://www.orexigen.com/
标题:Orexigen Therapeutics, Inc. - Home
关键字:Orexigen Therapeutics, Inc.
描述:Orexigen Therapeutics, Inc.
主体:
网址:http://www.orexigen.com/
标题:Orexigen Therapeutics, Inc. - Home
关键字:Orexigen Therapeutics, Inc.
描述:Orexigen Therapeutics, Inc.
主体:
Orexigen HomeAbout OrexigenCompany ProfileSenior ManagementBoard of DirectorsCollaborationsCorporate GovernanceProduct CandidatesOur Approach to Obesity TreatmentNB-32EmpaticAbout ObesityAbout ObesityWeight Control Circuit VideoObesity LinksNews & ResourcesInvestor RelationsCorporate ProfileStock InformationOwnership SummaryCorporate GovernanceEvents, Presentations, and WebcastsAnalyst CoverageSEC FilingsAnnual Report/ProxyEmail AlertsInformation RequestClinical TrialsOngoing Clinical TrialsQ&A About Clinical TrialsParticipationCareersOverviewMeet Some of the TeamHealth and Financial BenefitsCareer Opportunities OREXIGEN THERAPEUTICS, INC. We are a biopharmaceutical company focused on the treatment of obesity... ABOUT OREXIGEN Get to know our leadership team and learn about our collaborators... ABOUT OBESITY Did you know? Nearly 93 million Americans are affected by obesity... PRODUCT CANDIDATES Learn more about our product candidates for the treatment of obesity: NB-32 and Empatic™ CLINICAL TRIALS What is a clinical trial? How does it work? Find out here. WHO WE ARE Meet the team and learn about exciting career opportunities at Orexigen... OREXIGEN THERAPEUTICS, INC. We are a biopharmaceutical company focused on the treatment of obesity... « 01 02 03 04 05 06 07 » Pause Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd. ABOUT OBESITY Obesity is a serious and rising health epidemic in our country. It is a condition associated with having an excess of body fat, defined by genetic and environmental factors that are difficult to control when dieting. Obesity is classified as having a Body Mass Index (BMI) of 30 or greater. The Light Study is a multicenter, randomized, double-blind, placebo-controlled long-term research study of NB-32 (naltrexone SR/bupropion SR), an investigational drug being evaluated for weight loss. Who We Are "I joined Orexigen to be an integral member of a team of highly talented individuals who are working together to bring effective medicines..." - Jim NEWS & ANNOUNCEMENTS Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013 Copyright© 2014 Orexigen Therapeutics, Inc.. All rights reserved. Privacy PolicyTerms & ConditionsContact UsSite Map
最近查询网站